Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S3-S11

  Wyles, David L ^a,d   Sulkowski, Mark S ^b   Dieterich, Douglas ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

direct acting antivirals (DAAs); HCV; hepatitis C; HIV; HIV HCV coinfection

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; CREATININE; DACLATASVIR; DARUNAVIR; DASABUVIR; DOLUTEGRAVIR; EFAVIRENZ; ELBASVIR; EMTRICITABINE; ENTECAVIR; GRAZOPREVIR; HEMOGLOBIN A1C; INTERFERON; LAMIVUDINE; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; LOPINAVIR; NEVIRAPINE; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOFOSBUVIR; TACROLIMUS; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; ASTHENIA; BODY MASS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHILD PUGH SCORE; CHRONIC HEPATITIS B; COINFECTION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ELASTOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FOLLOW UP; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MEN WHO HAVE SEX WITH MEN; MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; NONALCOHOLIC FATTY LIVER; PATIENT CARE; PETECHIA; PHYLOGENY; PHYSICIAN; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; REINFECTION; SAFE SEX; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; COMPLICATION; DISEASE MANAGEMENT; LIVER DISEASE; MIXED INFECTION; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; COINFECTION; DISEASE MANAGEMENT; DISEASE PROGRESSION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 84995786016     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw219     Document Type: Article

References (59)

1. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195–207.
2. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord All-cause mortality in treated HIV-infected adults with CD4≥500/ mm3 compared with the general population: evidence from a large European observational collaboration. Int J Epidemiol 2012; 41:433–45.
3. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335–43.
4. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831–7.
5. Frederick T, Burian P, Terrault N, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009; 23:915–23.
6. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn PA. Comorbidityrelated treatment outcomes among HIV-infected adults in the Bronx, NY. J Urban Health 2011; 88:507–16.
7. Raymond HF, Hughes A, O’Keefe K, Stall RD, McFarland W. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. Sex Transm Dis 2011; 38:219–20.
8. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(suppl 1):S6–9.
9. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group. Hepatology 1999; 30:1054–8.
10. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562–9.
11. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209–16.
12. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51:1445–9.
13. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181–91.
14. MacBrayne CE, Kiser JJ. Pharmacologic considerations in the treatment of hepatitis C virus in persons with HIV. Clin Infect Dis 2016; 63(suppl 1):12–23.
15. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241–8.
16. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506–12.
17. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603–8.
18. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452–60.
19. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690–5.
20. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365–71.
21. Justice AC, Freiberg MS, Tracy R, et al. VACS Project Team. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984–94.
22. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658–66.
23. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV co-infection and the effect of anti-HBV nucleos(t)ide therapy. Clin Infect Dis 2014; 59:1027–31.
24. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, et al. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014; 58:719–27.
25. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622–30.
26. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61:730–40.
27. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361–9.
28. Martel-Laferrière V, Wong M, Dieterich DT. HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis 2014; 58:840–7.
29. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
30. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451–9.
31. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438–50.
32. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975–82.
33. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594–603.
34. Martin TC, Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013; 27:2551–7.
35. Rockstroh JK, Nelson M, Katlama C, et al. High efficacy of grazoprevir/elbasvir (GZR/EBR) in HCV genotype 1, 4, and 6-infected patients with HIV co-infection: SVR24 data from the phase 3 C-EDGE Co-infection Study. Hepatology 2015; 62 (suppl 1):317A.
36. Osinusi A, Townsend K, Kohil A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232–9.
37. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223–31.
38. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med 2015; 373:705–13.
39. German P, Garrison K, Pang PS, et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
40. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med 2015; 373:714–25.
41. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604–14.
42. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973–82.
43. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983–92.
44. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359–65.e1.
45. Ruane P, Adeyemi O, Trinh R, et al. TURQUOISE-I study: use of ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in patients with HCV/HIV-1 co-infection on stable darunavir-containing antiretroviral therapy [abstract LBPS7/1]. In: 15th EACS. Barcelona, Spain, 21–24 October, 2015.
46. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc., 2016.
47. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319–27.
48. Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Available at: http://www.aasld.org/sites/default/files/documents/2015/TLM_Abstracts/LB22.pdf. Accessed 17 February 2016.
49. Christensen S, Ingiliz P, Hueppe D, et al. German cohort on sofosbuvir based therapy for HCV/HIV- and HCV-infection (GECOSO). In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
50. Christensen S, Mauss S, Hueppe D, et al. Directly acting agents against HCV—results from the German hepatitis C cohort (GECCO). In: Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22–25 February 2016.
51. Gilmore J, Lynn K, Breen D, et al. Effectiveness of sofosbuvir/simeprevir for HIV/ HCV patients in clinical practice. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
52. Marks KM, Weinberg EM, Kumar S, et al. Sofosbuvir, simeprevir, +/- ribavirin in HCV protease inhibitor-experienced patients. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
53. Grant J, Stosor V, Palella F, et al. Successful treatment with direct acting antivirals in HIV/HCV patients. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
54. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1075–86.
55. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77–87.
56. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV co-infection. JAMA 2014; 312:353–61.
57. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385:1098–106.
58. Hill A, Simmons B, Saleem J, Cooke G. Risk of late relapse or re-infection with hepatitis C after sustained virological response: meta-analysis of 66 studies in 11,071 patients. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
59. Lambers FA, Brinkman K, Schinkel J, et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011; 25:1333–6.